{
    "thread": {
        "uuid": "b3fbba00905e5e8bf29e45644afe500f4d936bc6",
        "url": "https://insights.citeline.com/scrip/therapeutic-category/immunological/maat-prepares-for-ema-filing-us-expansion-after-positive-gvhd-readout-UDRSPUYZDVB5XHBUNOY42HVGFY",
        "site_full": "insights.citeline.com",
        "site": "citeline.com",
        "site_section": "https://insights.citeline.com/scrip/therapeutic-category",
        "site_categories": [],
        "section_title": "Therapy Areas: Alimentary, Anti-Infective, Cardiovascular &amp; More | Scrip",
        "title": "MaaT Prepares For EMA Filing, US Expansion After Positive GVHD Readout",
        "title_full": "MaaT Prepares For EMA Filing, US Expansion After Positive GVHD Readout",
        "published": "2025-01-10T00:35:00.000+02:00",
        "replies_count": 0,
        "participants_count": 1,
        "site_type": "news",
        "country": "US",
        "main_image": "https://insights.citeline.com/resizer/v2/3DQRDM2D6NKINHNP4K4IZXTGNE.jpg?smart=true&amp;auth=ee020e5a49bab4c7f5b4db77d39ce2dbff15f1b869cb427ee9d7a0fffadd7455&amp;width=1200&amp;height=630",
        "performance_score": 0,
        "domain_rank": 88865,
        "domain_rank_updated": "2025-01-06T23:00:00.000+02:00",
        "social": {
            "facebook": {
                "likes": 0,
                "comments": 0,
                "shares": 0
            },
            "vk": {
                "shares": 0
            }
        }
    },
    "uuid": "b3fbba00905e5e8bf29e45644afe500f4d936bc6",
    "url": "https://insights.citeline.com/scrip/therapeutic-category/immunological/maat-prepares-for-ema-filing-us-expansion-after-positive-gvhd-readout-UDRSPUYZDVB5XHBUNOY42HVGFY",
    "ord_in_thread": 0,
    "parent_url": null,
    "author": "-",
    "published": "2025-01-10T00:35:00.000+02:00",
    "title": "MaaT Prepares For EMA Filing, US Expansion After Positive GVHD Readout",
    "text": "MaaT Pharma is planning to first target the European market with MaaT013 for acute graft-versus-host disease with gastrointestinal involvement (GI-aGVHD) as it seeks to raise money to bring its microbiome-based drug to the US market.",
    "highlightText": "",
    "highlightTitle": "",
    "highlightThreadTitle": "",
    "language": "english",
    "sentiment": "positive",
    "categories": [
        "Health",
        "Science and Technology",
        "Economy, Business and Finance"
    ],
    "topics": [
        "Health->health organisation",
        "Health->medical specialisation",
        "Health->health treatment and procedure",
        "Science and Technology->biotechnology",
        "Science and Technology->medical research",
        "Economy, Business and Finance->healthcare industry",
        "Economy, Business and Finance->financial and economic news",
        "Economy, Business and Finance->business strategy and marketing"
    ],
    "ai_allow": true,
    "has_canonical": false,
    "breaking": null,
    "webz_reporter": false,
    "external_links": [],
    "external_images": [],
    "entities": {
        "persons": [],
        "organizations": [],
        "locations": []
    },
    "syndication": {
        "syndicated": false,
        "syndicate_id": null,
        "first_syndicated": false
    },
    "rating": null,
    "crawled": "2025-01-10T02:29:42.447+02:00",
    "updated": "2025-01-10T02:29:42.447+02:00"
}